The Hidden Invader: Tracking a Deadly Tapeworm in the Pacific Northwest

By Latest Epidemiological Data

Nature is full of invisible dramas. Right now, in the forests, suburbs, and even city parks of the Pacific Northwest, a microscopic shift is happening. If you are a dog owner, a hiker, or just someone living in Washington, Oregon, or British Columbia, you need to know about Echinococcus multilocularis.

While learning about parasites can be deeply unsettling—especially when they affect our pets and our health—it is important to ground ourselves in reality. Human cases are exceedingly rare, and the disease is highly preventable.

Here is the complete story of how a deadly tapeworm quietly moved into the West Coast, broken down into three parts: an easy primer, a deep dive for science enthusiasts, and a comprehensive clinical review for scientists and medical professionals.

Part 1: The Basics (What You Need to Know)

Let’s start with the simple facts. What exactly is happening in the Pacific Northwest?

Earlier this year, in the spring of 2026, researchers from the University of Washington made a surprising discovery. They were studying wild coyotes in the Puget Sound area—places like Seattle, Everett, and Whidbey Island. When they tested these animals, they found a tiny, highly dangerous tapeworm called Echinococcus multilocularis in 37% of the coyotes. That is more than one in three. Before this study, this specific tapeworm had never been officially documented in wild animals on the contiguous U.S. West Coast.

What is this tapeworm?

Echinococcus multilocularis is a tiny worm, barely a few millimeters long. In nature, it relies on two types of animals to survive:

• The Carrier (Coyotes and Foxes): The adult worms live in the intestines of wild canines. The coyote doesn't get sick at all. It just carries the worms and poops out thousands of invisible eggs into the soil and grass.
• The Prey (Mice and Voles): Small rodents eat food or grass contaminated with the eggs. The eggs hatch inside the rodent and grow into cysts in their liver, making the rodent weak. The coyote then eats the slow rodent, and the cycle starts all over again.

How does this affect us?

The problem happens when domestic dogs or humans accidentally step into this natural cycle.

If your dog eats an infected wild mouse, your dog can become a carrier, just like the coyote. Your dog won't look sick, but it will start shedding tapeworm eggs in your backyard.

Humans get infected by accidentally swallowing the eggs. This usually happens through "hand-to-mouth" contact. For example, if you pet a dog that has tapeworm eggs on its fur, and then you eat a sandwich without washing your hands, you can swallow the eggs. You can also get it by eating unwashed wild berries picked near coyote droppings.

The Disease

If a human or a dog swallows the eggs, the body reacts the same way a mouse's body does. The eggs hatch, travel to the liver, and begin forming cysts. This disease is called Alveolar echinococcosis (AE). It is dangerous because it acts almost exactly like liver cancer. The cysts grow slowly and silently over 5 to 15 years, eventually destroying the liver and spreading to other organs. If left untreated, it can be fatal.

How to Protect Yourself

• Wash your hands with soap and warm water after petting dogs, working in the garden, or playing outside.
• Keep your dog on a leash on trails so they don’t hunt or eat wild mice and voles.
• Talk to your vet about deworming medications. Standard heartworm pills don't kill tapeworms; your dog needs a specific medication containing praziquantel.
• Wash wild-foraged foods thoroughly before eating.

Part 2: The Evolving Ecology (For the Science Enthusiast)

If you are fascinated by nature, wildlife biology, and how ecosystems shift, the story of Echinococcus multilocularis in North America is a gripping case study in globalization and urban ecology.

To understand how this parasite arrived in Washington State, we have to look at its history and its highly complex life cycle.

The Geography of a Parasite

Historically, E. multilocularis was considered a problem of the Old World—heavily endemic to central Europe, Russia, and parts of Asia, with isolated pockets in the Arctic tundra. In North America, it was incredibly rare, mostly confined to remote northern regions of Canada and Alaska.

However, about 15 years ago, the narrative shifted. Wildlife biologists began noticing the parasite moving southward and eastward into the Canadian provinces of Alberta and Ontario, and eventually into the American Midwest.

But the West Coast remained seemingly untouched. That illusion broke in 2026. The study published in PLOS Neglected Tropical Diseases confirmed that the parasite hasn't just arrived in Washington; it has firmly established a transmission cycle. Finding a 37% prevalence rate means the parasite has likely been circulating under the radar for years.

Tracking the Genetic Fingerprint

How did it get to the Pacific Northwest? To answer this, scientists sequence the parasite's DNA.

The researchers discovered that the tapeworms in Washington coyotes belong to a specific genetic strain—or haplotype—known as mtG h28 (sometimes called the BC1 variant). This exact genetic fingerprint was first identified in a domestic dog in Quesnel, British Columbia, Canada. Furthermore, this Canadian strain originally traces its ancestry back to Europe.

This genetic breadcrumb trail paints a fascinating picture. It suggests that European strains of the tapeworm were brought to North America (possibly via unregulated movement of domestic dogs) and slowly moved through the wildlife populations of British Columbia. Over time, the parasite crossed mountain ranges and traveled nearly 800 kilometers southward into the Puget Sound ecosystem.

The Mechanics of the Infection

The danger of this parasite lies in its dual identity.

In its definitive hosts (coyotes, foxes, and domestic dogs), the parasite is a mature tapeworm. A single coyote can harbor tens of thousands of these adult worms in its small intestine. Because the worms are only about 1.5 to 3 millimeters long, they don't block the intestine or deprive the coyote of significant nutrients. The host lives a completely normal life, acting as an asymptomatic factory.

When an intermediate host (like a vole) or an accidental host (like a human) ingests the eggs, the true pathology begins. The eggs pass through the stomach and hatch into larvae in the intestines. These larvae burrow through the intestinal wall, enter the bloodstream, and are filtered out by the liver.

Once in the liver, the parasite undergoes a radical transformation. It doesn't grow into a tapeworm. Instead, it develops into a multi-chambered, fluid-filled cyst. Unlike normal cysts, which have clean, defined borders, the E. multilocularis cyst acts like a malignant tumor. It buds outward, infiltrating surrounding liver tissue, destroying blood vessels, and eventually sending pieces of itself (metastases) to the lungs and the brain.

The Urban Coyote Factor

Why are we seeing this in highly populated areas like Seattle and Everett? The answer lies in how we have changed the landscape. Coyotes are highly adaptable. As human development expands, coyotes have learned to thrive in urban and suburban environments.

This creates a synanthropic cycle—a wildlife disease cycle that occurs in close proximity to humans. The coyotes eat infected urban rodents, the coyotes defecate in public parks and backyards, and our domestic dogs roll in or sniff the contaminated soil. By bridging the gap between the deep forest and the suburban backyard, the urban coyote has inadvertently brought a serious public health risk to our doorsteps.

Part 3: Clinical & Epidemiological Review (For Scientists and Medical Professionals)

For epidemiologists, parasitologists, and clinicians, the emergence of Echinococcus multilocularis in the Pacific Northwest represents a critical intersection of veterinary medicine, genomics, immunology, and public health. The 2026 findings from Washington State necessitate a fundamental update to differential diagnoses for hepatic lesions in West Coast patients.

Molecular Epidemiology and Surveillance Limitations

E. multilocularis is a zoonotic cestode belonging to the order Cyclophyllidea. Historically, surveillance in wild canids relied on necropsy and morphological identification via the sedimentation and counting technique (SCT) of intestinal contents.

In recent years, the shift toward non-invasive fecal DNA metabarcoding has been championed as a cost-effective surveillance tool. However, the 2026 PLOS study highlighted a critical methodological flaw: DNA metabarcoding often severely underestimates the prevalence of E. multilocularis. The researchers utilized next-generation sequencing, specifically targeting the mitochondrial cytochrome c oxidase subunit 1 (cox1) and NADH dehydrogenase subunit 2 (nad2) genes. They found that amplification differences between intestinal tissue samples and field-collected scat led to false negatives in fecal-only testing.

Host-Parasite Immunology: Evading the Defenses

The pathophysiology of Alveolar echinococcosis (AE) is defined by the parasite's remarkable ability to modulate the host's immune system.

When the oncosphere (larva) reaches the hepatic parenchyma, it begins to develop into the metacestode stage. The parasite secretes a carbohydrate-rich, mucin-heavy matrix called the laminated layer. This physical barrier is highly resistant to host-derived nitric oxide and prevents direct contact between host immune cells and the parasite's living syncytium (the germinal layer).

More insidiously, the parasite actively skews the host's immune response. In the early stages of infection, the host mounts a robust Th1-mediated cellular response, characterized by the secretion of Interleukin-12 (IL-12) and Interferon-gamma (IFN-γ). This attempts to wall off the parasite via granuloma formation.

However, as the infection progresses, E. multilocularis secretes immunomodulatory molecules that force a shift toward a Th2-dominated response. This is marked by an increase in IL-4, IL-10, and Transforming Growth Factor-beta (TGF-β). This Th2 shift induces a state of localized immune tolerance or "anergy," suppressing macrophage activation and allowing the multivesicular cyst to proliferate unchecked through the liver tissue.

Clinical Pathology and Diagnostics in Accidental Hosts

In humans, AE has an asymptomatic incubation period spanning 5 to 15 years. Because of its rarity in North America, misdiagnosis is common. The infiltrative, exophytic growth pattern of the metacestode closely mimics primary hepatic malignancies, particularly hepatocellular carcinoma (HCC) or cholangiocarcinoma.

• Clinical Presentation: Patients typically present with right upper quadrant pain, hepatomegaly, malaise, and weight loss. If the parasitic mass invades the biliary tree, obstructive jaundice and secondary bacterial cholangitis often occur.
• Diagnostic Imaging: Ultrasonography (US) often reveals heterogeneous, poorly defined hepatic masses with central necrosis and a "hailstorm" pattern of microcalcifications. CT and MRI are essential for staging and assessing biliary/vascular invasion.
• Serodiagnosis: Biopsy is contraindicated due to the risk of anaphylaxis or secondary seeding. Diagnosis relies on serology. Enzyme-linked immunosorbent assays (ELISA) utilizing purified recombinant antigens, specifically Em2 and Em18, are standard.

Therapeutics and Management Protocols

The clinical management of AE is complex and staged using the WHO-PNM system (Parasite mass, Neighboring organ involvement, Metastases).

1. Surgical Intervention: The gold standard for curative treatment is radical hepatectomy with negative margins (R0 resection). However, due to the insidious onset of the disease, fewer than 30% of patients present with operable lesions.

2. Pharmacotherapy: Whether a patient undergoes curative surgery or is deemed inoperable, pharmacotherapy is mandatory. The foundation of treatment relies on benzimidazoles—primarily albendazole (ABZ) or mebendazole (MBZ).

Crucial Clinical Caveat: In the human body, benzimidazoles are parasitostatic, not parasiticidal. They halt the growth of the cysts but do not reliably kill the germinal layer. Consequently:

• Patients who undergo successful R0 resection must remain on albendazole therapy for a minimum of 2 years post-operatively.
• Patients with inoperable lesions are committed to lifelong continuous albendazole therapy.

The Path Forward: A One Health Imperative

The detection of E. multilocularis in 37% of surveyed coyotes in the Pacific Northwest is a blaring alarm for public health infrastructure. Addressing this requires a unified "One Health" approach involving mandatory veterinary policy updates for domestic dog transport, enhanced physician education on atypical hepatic masses, and systematic continent-wide wildlife surveillance.

Tags: Epidemiology, Public Health, Pacific Northwest, Zoonotic Diseases, Echinococcus multilocularis, One Health